IP Library Granted Patent US 9,789,222
Granted Patent B2
US 9,789,222 · App. 15/139,632 · Granted Oct 17, 2017

Injectable alloplastic implants and methods of use thereof

Inventor: Louis Masi (Longmeadow, MA)
Assignee: SUNEVA MEDICAL, INC.
A61L27/16A61L27/24A61L27/26A61L27/48A61L27/54A61L2400/06A61L2430/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,789,222
App. No.
15/139,632
Granted
Oct 17, 2017
Kind
B2
Abstract

Described herein are injectable alloplastic implant compositions that are particularly useful for soft tissue defect augmentation. The compositions include microparticles, such as polymethylmethacrylate particles, and collagen as a suspending agent, wherein the collagen contains a reduced amount of low molecular weight gelatine compared to high molecular weight collagen. By controlling the molecular weight of the collagen in the compositions, the injectability, stability, and antigenicity of the alloplastic implant compositions can be improved.

Claims (12)

1. A method of injecting an injectable alloplastic implant composition, comprising injecting the injectable alloplastic implant composition through a 20 to 30 gauge needle, the injectable alloplastic implant composition comprising

microparticles having a diameter of about 5 to about 400 μm suspended in an aqueous suspending agent,

wherein the aqueous suspending agent comprises denatured type I collagen or atelocollagen, wherein the denatured type I collagen or atelocollagen has less than 10 wt % of the total weight as components of weight average molecular weight (Mw) 100,000 Daltons or lower, and greater than 70 wt % components of weight average molecular weight 100 kDa to 258 kDa,

wherein the polydispersity of the denatured type I collagen or atelocollagen expressed as Mw/Mn is 1.0 to 1.6, wherein Mw is weight average molecular weight and Mn is number average molecular weight.

2. The method of claim 1 , wherein the denatured type I collagen or atelocollagen is prepared from bovine or porcine collagen.

3. The method of claim 1 , wherein the pH of the aqueous suspending agent is 6.0 to 8.0 and the concentration of denatured type I collagen or atelocollagen in the aqueous suspending agent is 0.5 to 15 wt %.

4. The method of claim 1 , wherein the microparticles have a diameter of about 10 to about 200 μm.

5. The method of claim 1 , wherein the microparticles comprise a polymer or copolymer comprising a methacrylate monomer.

6. The method of claim 5 , wherein the polymer or copolymer is polymethylmethacrylate.

7. The method of claim 1 , wherein the injectable alloplastic implant composition further comprises an anesthetic.

8. The method of claim 1 , wherein the injectable alloplastic implant composition is stable for at least 30 days at a temperature of 20-25° C.

9. The method of claim 1 , wherein the injectable alloplastic implant composition is stable for 72 hours at room temperature.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 22, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: SUNEVA MEDICAL, INC.
Reel/Frame 068968/0598 →
SECURITY INTEREST Recorded Aug 24, 2021
From: SUNEVA MEDICAL, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
Reel/Frame 057277/0460 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2016
From: MASI, LOUIS
To: SUNEVA MEDICAL, INC.
Reel/Frame 038995/0732 →
CHANGE OF ASSIGNEE ADDRESS Recorded Jun 23, 2016
From: SUNEVA MEDICAL, INC
To: SUNEVA MEDICAL, INC.
Reel/Frame 039139/0433 →
Continuity (3)
Continuation 14657274 · Mar 13, 2015
Continuation In Part 14211994 · Mar 14, 2014
Related Publication 20160235887A1 · Aug 18, 2016